Cytarabine

Catalog No.S1648

Cytarabine Chemical Structure

Molecular Weight(MW): 243.22

Cytarabine is an antimetabolic agent and DNA synthesis inhibitor with IC50 of 16 nM in wild-type CCRF-CEM cells.

Size Price Stock Quantity  
USD 97 In stock
USD 970 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

3 Customer Reviews

  • Viability and CI vs Fa after 24-h exposure to cytarabine alone or in combination with ABT-199 in Riva, U2932 and VavP-Bcl2/c-MYC murine tumor cells. Viability shown at 500 nM (500 ng/ml for cytarabine; quadruplicates±s.e.m.).

    Leukemia, 2015, 29(8): 1702–1712. Cytarabine purchased from Selleck.

    Cell cycle was analyzed using propidium iodide (PI) staining and flow cytometry. The plots show PI staining at the x-axis and cell counts at the y-axis. The graphs were prepared using ModFit LT™ software (Verity Software House). Nd: not detected, Ara-c:Cytarabine

    J Exp Clin Cancer Res, 2017, 36(1):22. Cytarabine purchased from Selleck.

  • Flow cytometry analysis for cell surface expression of CD11b shows time- and dose-dependent upregulation of the marker CD11b in MLL-rearranged leukemia cells treated with EPZ-5676 and Cytarabine(Ara-C) as single agents and in combination.

    J Pharmacol Exp Ther, 2014, 350(3): 646-56. Cytarabine purchased from Selleck.

Purity & Quality Control

Choose Selective DNA/RNA Synthesis Inhibitors

Biological Activity

Description Cytarabine is an antimetabolic agent and DNA synthesis inhibitor with IC50 of 16 nM in wild-type CCRF-CEM cells.
Features The 1st of a series of cancer drugs that alters the sugar component of nucleosides.
Targets
DNA synthesis [1]
(CCRF-CEM cells)
16 nM
In vitro

Cytarabine (AraC) is phosphorylated into a triphosphate form (Ara-CTP) involving deoxycytidine kinase (dCK), which competes with dCTP for incorporation into DNA, and then blocks DNA synthesis by inhibiting the function of DNA and RNA polymerases. Cytarabine displays a higher growth inhibitory activity towards wild-type CCRF-CEM cells compared to other acute myelogenous leukemia (AML) cells with IC50 of 16 nM. [1] Increasing concentrations of Cytarabine (IC50 of 0.69 μM) results in decreased metabolic activity of sensitive rat leukemic cell line RO/1, and the cell toxity can be highly enhanced by transfection with human wt dCK (IC50 of 0.037 μM) but not the inactive, alternatively spliced dCK forms. [2] Cytarabine apparently induces apoptosis of rat sympathetic neurons at 10 μM, of which 100 μM shows the highest toxicity and kills over 80% of the neurons by 84 hours, involving the release of mitochondrial cytochrome-c and the activation of caspase-3, and the toxicity can be attenuated by p53 knockdown and delayed by bax deletion. [3]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
mouse L1210 cells Mn;sR5l1d3SxeHnjxsBie3OjeR?= MYKzJIRigXN? MnjmR5l1d3SxeHnjbZR6KGGpYXnud5Qh\GWxeInueYNt\W:|aXTlJIFv[WyxZ4XlMZNmdnOrdHn2[UBud3W|ZTDMNVIyOCClZXzsd{Bi\nSncjCzJIRigXNiYomgUXRVKGG|c3H5MEBKSzVyPUCuOEBvVS5? M4f3[VE6Pjd2OUCz
human CCRF-CEM cells MX\DfZRwfG:6aXRCpIF{e2G7 NIKwWow{KGSjeYO= MYnDfZRwfG:6aXPpeJkh[WejaX7zeEBl\W:6eX71Z4xmd3OrZHWgZY5idG:pdXWtd4Vve2m2aY\lJIh2dWGwIFPDVmYuS0WPIHPlcIx{KGGodHXyJFMh\GG7czDifUBOXFRiYYPzZZktKEmFNUC9NUBvVS5? MXWxPVY4PDlyMx?=
human MCF7 cells MULDfZRwfG:6aXRCpIF{e2G7 NID6[4g{KGSjeYO= M2jsdGN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGSnb4j5cpVkdGWxc3nk[UBidmGub3f1[U1{\W6|aYTpeoUhcHWvYX6gUWNHPyClZXzsd{Bi\nSncjCzJIRigXNiYomgUXRVKGG|c3H5MEBKSzVyPUSgcm0v MUGxPVY4PDlyMx?=
CCRF-CEM cell line NIXnTHVHfW6ldHnvckBie3OjeR?= MkjMTY5pcWKrdDD0bIUhemWybHnjZZRqd25ib3[gR2NTTi2FRV2gZ4VtdCCuaX7lJIlvKH[rdILvMEBGTDVyPUWgcm0v NXHFWlJmOTl7NUi5OC=>
human P12-ICHIKAWA cell NUHvS3BNT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NXf5O2lwUW6qaXLpeIlwdiCxZjDoeY1idiCSMUKtTWNJUUuDV1GgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME21MlU1KG6PLh?= NUXi[nAxW0GQR1XS
human CCRF-CEM cells M3OxeGN6fG:2b4jpZ:Kh[XO|YYm= Mk[wOFghcA>? M2ryWmN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJGNEWkZvQ1XNJINmdGy|IHHmeIVzKDR6IHjyd{BjgSClZXzsJJRqfGW{LXLseYUh[XO|YYmsJGVEPTB;NT62NUBvVS5? MWGxPVc1Ozh3OB?=
CCRF-CEM cell lines MWDGeY5kfGmxbjDhd5NigQ>? M2H6WVczKGh? M4rCWmNwdmOnboTyZZRqd25icnXxeYlz\WRidH:gbY5pcWKrdDDy[ZBtcWOjdHnvckBw\iCFQ2LGMWNGVSClZXzsJIxqdmW|IHL5JFUxLSCjZoTldkA4OiCqcjDpcoN2[mG2aX;uMEBGTDVyPU[gcm0v NF;ZPGsyPjV{MEK0
human CCRF-CEM cells NE\hcGZEgXSxdH;4bYPDqGG|c3H5 MYe0PEBp MoTUR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gR2NTTi2FRV2gZ4VtdHNiYYPz[ZN{\WRiYYOgZ4VtdCC4aXHibYxqfHliYX\0[ZIhPDhiaILzJIJ6KGOnbHz0bZRmei2kbIXlJIF{e2G7LDDJR|UxRTZibl2u NXTvS29vOjJ3OEK5PVE>
human SF268 cells NYfi[VZXS3m2b4TvfIlkyqCjc4PhfS=> M1LuNmN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJHNHOjZ6IHPlcIx{KGK7IF3UWEBie3OjeTygTWM2OD15Lk[4JI5ONg>? Mm\YNVk{PDV3OEG=
MOLT-4 human leukemic lymphoblastoid cell lines MoDzR5l1d3SxeHnjxsBie3OjeR?= NFn6UJZEgXSxdH;4bYNqfHliYXfhbY5{fCCPT1zUMVQhcHWvYX6gcIV2c2WvaXOgcJlueGixYnzhd5RwcWRiY3XscEBtcW6nczygTWM2OD1zMDDuUU4> MkL6OlgzPzV2Nh?=
human 697 cell Mn[yS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MVfJcohq[mm2aX;uJI9nKGi3bXHuJFY6PyClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTFyLk[gcm0v NV7nXmN7W0GQR1XS
human ES1 cell NFrNXJRIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MlXMTY5pcWKrdHnvckBw\iCqdX3hckBGWzFiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1zMj65O{BvVS5? NEL3T|NUSU6JRWK=
CCRF-CEM human leukemic lymphoblastoid cell lines M1\6emN6fG:2b4jpZ:Kh[XO|YYm= NFfJNllEgXSxdH;4bYNqfHliYXfhbY5{fCCFQ2LGMWNGVSCqdX3hckBt\XWtZX3pZ{BtgW2yaH;icIF{fG:rZDDj[YxtKGyrbnXzMEBKSzVyPUKwJI5ONg>? MWi2PFI4PTR4
P388 murine cell lines MlzISpVv[3Srb36gZZN{[Xl? MkXtO|IhcA>? MmXUWIhmKGOxbYDveY5lKHejczD0[ZN1\WRiaX6geol1em9iZn;yJIFvfGm2dX3vdkBi[3Srdnn0fUg2OCViaX7obYJqfGmxbjDv[kB1fW2xcjDj[YxtKGe{b4f0bEkh[WejaX7zeEB1cGViUEO4PEBufXKrbnWgZ4VtdCCuaX7ld{Bi\nSncjC3NkBpd3W{czygTWQ2OD1{MDDuUU4> M1PXOlM3OjV5MUS=
L1210 murine cell lines MWPGeY5kfGmxbjDhd5NigQ>? NIHhZ484OiCq MWrUbIUh[2:vcH;1coQhf2G|IITld5Rm\CCrbjD2bZRzdyCob4KgZY51cXS3bX;yJIFkfGm4aYT5LFUxLSCrbnjpZol1cW:wIH;mJJR2dW:{IHPlcIwh\3Kxd4ToLUBi\2GrboP0JJRp\SCOMUKxNEBufXKrbnWgZ4VtdCCuaX7ld{Bi\nSncjC3NkBpd3W{czygTWQ2OD1{MDDuUU4> NEG2NIk{PjJ3N{G0
human HEL cell Mn;1S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NYXu[nFmUW6qaXLpeIlwdiCxZjDoeY1idiCKRVygZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2yNE42OiCwTT6= Mmi0V2FPT0WU
human CCRF-CEM/C2 cells NFHMfpJEgXSxdH;4bYPDqGG|c3H5 NWfRUopjPDhiaB?= M{TZVmN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJGNEWkZvQ1XNM2MzKGOnbHzzJIFnfGW{IES4JIhzeyCkeTDj[YxtKHSrdHXyMYJtfWViYYPzZZktKEWFNUC9NlIvQCCwTT6= NHi0U4QyQTd2M{i1PC=>
mouse L1210 cells NUnjSm9JS3m2b4TvfIlkyqCjc4PhfS=> NHixVGY1QCCq MVzDfZRwfG:6aXPpeJkh[WejaX7zeEBud3W|ZTDMNVIyOCClZXzsd{Bie3Onc4Pl[EBieyCrbnjpZol1cW:wIH;mJINmdGxicILvcIln\XKjdHnvckBi\nSncjC0PEBpenNuIFnDOVA:OC5yMkSg{txONg>? NHn3RmgzODByMESxPC=>
human CEM cells Mm\SR5l1d3SxeHnjxsBie3OjeR?= MmTvOFghcA>? M1vQU2N6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJGNGVSClZXzsd{Bie3Onc4Pl[EBieyCrbnjpZol1cW:wIH;mJINmdGxicILvcIln\XKjdHnvckBi\nSncjC0PEBpenNuIFnDOVA:OC5yMkSg{txONg>? NUfyTY0zOjByMEC0NVg>
human 2209-23 cells MmrwVJJwdGmoZYLheIlwdiCjc4PhfS=> NFTyR5BCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIEKyNFkuOjNiY3XscJMh[nliW{PIYZRpgW2rZHnu[UBqdmOxcoDvdoF1cW:wIIPjbY51cWyuYYTpc44heHKxeHntbZR6KGG|c3H5MEBKSzVyPUCuNFI6KM7:TR?= NWnlSIFLOTlyNUW0PFI>
human CHP-212 cell NUPFbIhRT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MV;Jcohq[mm2aX;uJI9nKGi3bXHuJGNJWC1{MUKgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2zN{41PyCwTT6= MnzhV2FPT0WU
human CTB-1 cell MYLHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NFv2UZJKdmirYnn0bY9vKG:oIHj1cYFvKEOWQj2xJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9N|QvOyCwTR?= M37oWnNCVkeHUh?=
human A427 cell M{DOfGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 M3zkXWlvcGmkaYTpc44hd2ZiaIXtZY4hSTR{NzDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUO0MlQ6KG6PLh?= M1Wwb3NCVkeHUh?=
human MOLT-16 cell MnnyS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? Mny4TY5pcWKrdHnvckBw\iCqdX3hckBOV0yWLUG2JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9N|YvODdibl2u M3rUVHNCVkeHUh?=
human MCF7 1K cells MYXDfZRwfG:6aXRCpIF{e2G7 M2PhUFMh\GG7cx?= NVfSWVg6S3m2b4TvfIlkcXS7IHHnZYlve3RiZHXvfJlvfWOuZX;zbYRmKGGwYXzv[5VmNXKnc3nzeIFvfCCqdX3hckBOS0Z5IEHLJINmdGy|IH;2[ZJmgHC{ZYPzbY5oKHKrYn;ueYNt\W:2aXTlJJJm\HWldHHz[UBi\nSncjCzJIRigXNiYomgUXRVKGG|c3H5MEBKSzVyPUSwJI5ONg>? MlLjNVk3PzR7MEO=
human MC-IXC cell NYDlOIl4T3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NXH3[25bUW6qaXLpeIlwdiCxZjDoeY1idiCPQz3JXGMh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF01OS52MTDuUU4> NF[4[YdUSU6JRWK=
human BHT-101 cell MWDHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MoPtTY5pcWKrdHnvckBw\iCqdX3hckBDUFRvMUCxJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9OFEvPzZibl2= Mk\oV2FPT0WU
human K5 cell NILkWWlIem:5dHigbY5pcWKrdHnvckBie3OjeR?= M3jHOGlvcGmkaYTpc44hd2ZiaIXtZY4hUzViY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD12Mz6yJI5O NHS2WXhUSU6JRWK=
parent promyelocytic leukemia cell line NV7qbYEyTnWwY4Tpc44h[XO|YYm= MVfBcpRq[2GwY3XyJIFkfGm4aYT5JJdieyCndnHseYF1\WRiZn;yJJRp\SClb33wc5Vv\CCjZ3HpcpN1KHCjcnXueEBxem:veXXsc4N6fGmlIHzleYtmdWmjIHPlcIwhdGmwZTCoTGwuPjBvR1jQVnQsN2SFSzupMEBGTDVyPUS3JI5ONg>? MXKzNFI4OzJ7
human HL60 cells MknWR5l1d3SxeHnjxsBie3OjeR?= NHHqV5hEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBJVDZyIHPlcIx{KGG|c3Xzd4VlKGG|IHPlcIwhfmmjYnnsbZR6KGGodHXyJFQ5KGi{czDifUBk\WyudHn0[ZIu[my3ZTDhd5NigSxiSVO1NF0xNjB2OTFOwG0v M{ThcVIzPTh{OUmx
human A549 cell NGrFZnhIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MnrJTY5pcWKrdHnvckBw\iCqdX3hckBCPTR7IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;NEmuOlYhdk1? MlWyV2FPT0WU
human NCI-H1703 cell MXvHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NF:5XFJKdmirYnn0bY9vKG:oIHj1cYFvKE6FST3INVcxOyClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTR7LkixJI5O NGS2SJlUSU6JRWK=
L1210 cell lines M2LIemZ2dmO2aX;uJIF{e2G7 MV7Dc45k\W62cnH0bY9vKHKncYXpdoVlKHSxIHnubIljcXRicnXwcIlk[XSrb36gc4YhVDF{MUCgZ4VtdCCuaX7ld{BjgSB3MDWgZYZ1\XJiN{KgbJIhcW6ldXLheIlwdixiRVS1NF0xNjB3IN88UU4> M1[1fVE3PTJyMkS=
human K562 cells NWnWUnpJS3m2b4TvfIlkyqCjc4PhfS=> MWXDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDLOVYzKGOnbHzzJIJ6KFOUQjDhd5NigSxiSVO1NF0xNjB3IN88US=> MoLvNlQ6PTZ3NU[=
human LB2241-RCC cell NGDhVoJIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NVnwR3Y6UW6qaXLpeIlwdiCxZjDoeY1idiCOQkKyOFEuWkOFIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;NUWuN|Qhdk1? M2PWPHNCVkeHUh?=
human MLMA cell NGntcWNIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MY\Jcohq[mm2aX;uJI9nKGi3bXHuJG1NVUFiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD13NT61NUBvVQ>? M{G5[HNCVkeHUh?=
human P30-OHK cell NEjhdlJIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MoT0TY5pcWKrdHnvckBw\iCqdX3hckBROzBvT1jLJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9OVYvPSCwTR?= M2q3eHNCVkeHUh?=
RPMI-6410 human leukemic lymphoblastoid cell lines NEPIXmhEgXSxdH;4bYPDqGG|c3H5 MkjhR5l1d3SxeHnjbZR6KGGpYXnud5QhWlCPST22OFExKGi3bXHuJIxmfWunbXnjJIx6dXCqb3LsZZN1d2mmIHPlcIwhdGmwZYOsJGlEPTB;MD6wOkDPxE1? NVvYTlhDPjh{N{W0Oi=>
human HT-29 cells M1LuVXBzd2yrZnXyZZRqd25iYYPzZZk> MnP2RY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6|dDDoeY1idiCKVD2yPUBk\WyuczDh[pRmeiB7NjDodpMh[nliTWTUJIF{e2G7LDDJR|UxRTBwME[2JO69VS5? M1LiOVI4Pzh2NEm=
human NCI-H510A cell MUjHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NUS0WW1qUW6qaXLpeIlwdiCxZjDoeY1idiCQQ1mtTFUyOEFiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD14OD6yOkBvVQ>? MmThV2FPT0WU
human J-RT3-T3-5 cell MVvHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NFLUPIhKdmirYnn0bY9vKG:oIHj1cYFvKEpvUmSzMXQ{NTViY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD14OD60NkBvVQ>? M4nSO3NCVkeHUh?=
human VA-ES-BJ cell M1y3NGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NYDPSXZ{UW6qaXLpeIlwdiCxZjDoeY1idiCYQT3FV{1DUiClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTdzLk[1JI5O M1r6SXNCVkeHUh?=
human T-24 cell NWi0UZhCT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NGX6TI9KdmirYnn0bY9vKG:oIHj1cYFvKFRvMkSgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME23PE42PiCwTR?= M3LaSXNCVkeHUh?=
human NB69 cell M3fqbWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 M1z5[WlvcGmkaYTpc44hd2ZiaIXtZY4hVkJ4OTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUe5MlQ5KG6P M1qybnNCVkeHUh?=
human BALL-1 cells M4HQcGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 M1HvVFI1KGh? MYHHdo94fGhiaX7obYJqfGmxbjDv[kBpfW2jbjDCRWxNNTFiY3XscJMh[W[2ZYKgNlQhcHK|IHL5JHdUXC1zIHHzd4F6NCCJSUWwQVAvODhizszN MojONlIzPjRzN{C=
HL60 cells NIDxPJdRem:uaX\ldoF1cW:wIHHzd4F6 MX\JckB3cXS{bzDpcohq[mm2b4L5JINwdmOnboTyZZRqd25iYXfhbY5{fCCycn;sbYZmemG2aX;uJI9nKEiONkCgZ4VtdHNuIFnDOVA:OC5yODFOwG0> M4j6cFEzQDd5NUmz
human CTV-1 cell MVPHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NFvrcVlKdmirYnn0bY9vKG:oIHj1cYFvKEOWVj2xJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9PFQvPzRibl2= NV;kU5FVW0GQR1XS
human MEL-JUSO cell NVHm[pJRT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NYLYVmJOUW6qaXLpeIlwdiCxZjDoeY1idiCPRVytTnVUVyClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTh3Lke2JI5O MYPTRW5ITVJ?
human MOLT-4 cell NHrV[5lIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NEDNbIhKdmirYnn0bY9vKG:oIHj1cYFvKE2RTGStOEBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVg6NjZ5IH7N NGPIenlUSU6JRWK=
human leukemia cell line(CCRF-CEM) NIjZU3dEgXSxdH;4bYPDqGG|c3H5 M1q3d2lvKH[rdILvJIN6fG:2b4jpZ4l1gSCxZjDjc41xd3WwZIOge4Vz\SCmZYTldo1qdmWmIH;uJGlvcGmkaYTpc44hd2ZiaIXtZY4hdGW3a3XtbYEh[2WubDDsbY5mMEOFUl[tR2VOMSxiSVO1NF0xNjB7IN88UU4> NHHT[GQ5QTF5NkS1
human SW982 cell M1m3d2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NIfGd5hKdmirYnn0bY9vKG:oIHj1cYFvKFOZOUiyJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9PVEvOjNibl2= MVPTRW5ITVJ?
human NCI-SNU-1 cell M3jhN2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7 M3HtcmlvcGmkaYTpc44hd2ZiaIXtZY4hVkOLLWPOWU0yKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XoxvJygTWM2OD17Nj63O{BvVQ>? NUGzV4hEW0GQR1XS
HeLa human cell lines NELvOGJHfW6ldHnvckBie3OjeR?= MkjONVQ1KGh? NInRVFBVcGViY3;tdI92dmRid3HzJJRme3SnZDDpckB3cXS{bzDmc5Ih[W62aYT1cY9zKGGldHn2bZR6MDVyJTDpcohq[mm2aX;uJI9nKHS3bX;yJINmdGxiZ4Lve5RpMSCjZ3HpcpN1KEinTHGgbJVu[W5iY3XscEBtcW6nczDh[pRmeiBzNESgbJItKEmGNUC9NE4yKM7:TR?= NFHL[JQ{PjJ3N{G0
human H460 cells MVzGeY5kfGmxbjDhd5NigQ>? NWPlVGF7OjRiaB?= NUm4RlR5SW62aYT1cY9zKGGldHn2bZR6KGGpYXnud5QhcHWvYX6gTFQ3OCClZXzsd{Bi\nSncjCyOEBpenNiYomgUXRVKGG|c3H5xsA> NIiybZYzODJzMUW2OC=>
human HCT116 cells M3nr[mZ2dmO2aX;uJIF{e2G7 MoPZRY51cXS3bX;yJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iSFPUNVE3KGOnbHzzJIFnfGW{IEK0JIhzeyCkeTDNWHQh[XO|YYmsJGlEPTB;MD6xJO69VQ>? M1TwSlIxOjFzNU[0
human GP5d cell NXPRPFQzT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NYrLT4J6UW6qaXLpeIlwdiCxZjDoeY1idiCJUEXkJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NVAzKG6P M4L0bHNCVkeHUh?=
human SAS cell MYTHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? M37ZSWlvcGmkaYTpc44hd2ZiaIXtZY4hW0GVIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;MUC3MlU4KG6P MX;TRW5ITVJ?
human BFTC-905 cell  MVnHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NInUd3JKdmirYnn0bY9vKG:oIHj1cYFvKEKIVFOtPVA2KGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:OTB6LkOxJI5O NHP2WmZUSU6JRWK=
human LB1047-RCC cell NG\jeHRIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MVrJcohq[mm2aX;uJI9nKGi3bXHuJGxDOTB2Nz3SR2Mh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0yODhwNEKgcm0> MoD0V2FPT0WU
human BB65-RCC cell M2n3bWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 M4iyRmlvcGmkaYTpc44hd2ZiaIXtZY4hSkJ4NT3SR2Mh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0yOTBwMUmgcm0> MVvTRW5ITVJ?
human KE-37 cell M2LwN2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7 M{P1cWlvcGmkaYTpc44hd2ZiaIXtZY4hU0VvM{egZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2xNVAvQDVibl2= NVnzOVZkW0GQR1XS
human NCI-H292 cell MlKyS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? M3TUSWlvcGmkaYTpc44hd2ZiaIXtZY4hVkOLLViyPVIh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0yOTRwMjDuUS=> Mk\BV2FPT0WU
human HT-1080 cell NU[4UoFuT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= M3PBcWlvcGmkaYTpc44hd2ZiaIXtZY4hUFRvMUC4NEBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVEyPC52NzDuUS=> Mlf0V2FPT0WU
human HL60 cells M{XVUmN6fG:2b4jpZ:Kh[XO|YYm= MVi0PEBp NYHxZ|NTS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hUEx4MDDj[YxteyCjZoTldkA1QCCqcoOgZpkhVVSWIHHzd4F6NCCLQ{WwQVAvOTF6IN88US=> NX3oWlRqOTl|MkGyN|Q>
human CAKI-1 cell M37nXGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MmHBS5Jwf3SqIHnubIljcXSrb36gc4Yh[WejaX7zeEBpfW2jbjDIR3QyOTZiY3XscJMh[W[2ZYKgNlQhcHK|IHL5JHdUXC1zIHHzd4F6NCCJSUWwQVAvOTJizszN Mlu0NlIzPjRzN{C=
human CAKI-1 cell MnTHS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NHTjbYNKdmirYnn0bY9vKG:oIHj1cYFvKEODS1mtNUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVEzOCCwTR?= MWfTRW5ITVJ?
human HMV-II cell NFT4eGJIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NHjDWHRKdmirYnn0bY9vKG:oIHj1cYFvKEiPVj3JTUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6 NYTHZ4t7W0GQR1XS
human ES8 cell Ml3nS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MkL6TY5pcWKrdHnvckBw\iCqdX3hckBGWzhiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1zMkOuPVMhdk1? MWLTRW5ITVJ?
human NEC8 cell NFzXVndIem:5dHigbY5pcWKrdHnvckBie3OjeR?= Mn7CTY5pcWKrdHnvckBw\iCqdX3hckBPTUN6IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;MUO0MlIyKG6P MlfTV2FPT0WU
human EW-1 cell MXTHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? M1vzcGlvcGmkaYTpc44hd2ZiaIXtZY4hTVdvMTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUGzPE43OiCwTR?= Mo[1V2FPT0WU
murine leukemia P388 MmntSpVv[3Srb36gZZN{[Xl? NHvFRlZCdnSrY3HuZ4VzKGGldHn2bZR6KGOjcoLp[YQhd3W2IHnuJJZqfHKxIHHnZYlve3RibYXybY5mKGyndXvlcYliKFB|OEisJGlEPTB;MD6xOEDPxE1? NEfYbm8yOTN3NkGxNC=>
human H-EMC-SS cell M13QNGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MlKwTY5pcWKrdHnvckBw\iCqdX3hckBJNUWPQz3TV{Bk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVE1PS5{ODDuUS=> NG\wb5hUSU6JRWK=
human SNU638 cells NHPYTlNEgXSxdH;4bYPDqGG|c3H5 MoHkR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gV25WPjN6IHPlcIx{KGK7IGPSRkBie3OjeTygTWM2OD1yLkG1JO69VQ>? NX3mbWw{OjR7NU[1OVY>
human COR-L105 cell MVPHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MnTsTY5pcWKrdHnvckBw\iCqdX3hckBEV1JvTEGwOUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVE3OC5|OTDuUS=> M1HSV3NCVkeHUh?=

... Click to View More Cell Line Experimental Data

In vivo Cytarabine is highly effective against acute leukaemias, which causes the characteristic G1/S blockage and synchronization, and increases the survival time for leukaemic Brown Norway rats in a weak dose-related fashion indicating that the use of higher dosages of Cytarabine does not contribute to its antileukaemic effectiveness in man. [4] Cytarabine (250 mg/kg) also causes placental growth retardation and increases placental trophoblastic cells apoptosis in the placental labyrinth zone of the pregnant Slc:Wistar rats, which increases from 3 hour after the treatment and peaks at 6 hour before returning to control levels at 48 hour, with remarkably enhanced p53 protein, p53 trancriptional target genes such as p21, cyclinG1 and fas and caspase-3 activity. [5]

Protocol

Kinase Assay:[1]
+ Expand

In Vitro Growth Inhibition Assay:

Stock solution of Cytarabine is prepared in absolute ethanol, and serial dilutions of Cytarabine are prepared. CCRF-CEM cells are suspended in RPMI medium supplemented with 10% FBS, 0.1% gentamicin, and 1% sodium pyruvate. The cells are suspended in their respective media to give 10 mL volumes of cell suspension at a final density of 3-6 × 104 cells/mL. Appropriate volumes of Cytarabine solution are transferred to the cell suspensions, and incubation is continued for 72 hours. The cells are spun down and resuspended in fresh Cytarabine -free medium, and final cell counts are determined. The data are analyzed by sigmoidal curve fitting of the cell count versus Cytarabine concentration, and the results are expressed as the IC50 (Cytarabine concentration that inhibits cell growth to 50% of the control value).
Cell Research:[2]
+ Expand
  • Cell lines: Rat leukemic cell lines RCL/0, RO/1 and K7 and human myelomonocytic leukemic U937
  • Concentrations: ~100 μM
  • Incubation Time: 24, 48 and 72 hours
  • Method: Cells are incubated in the presence of different concentrations of Cytarabine at 37 °C for 24, 48, and 72 hours. At the time of 20-, 44-, or 68-hour incubation in the presence of Cytarabine, 10 mL of cell proliferation reagent WST-1 solution is added. After 2- and 4-hour incubation with WST-1, cell metabolic activity is assessed with colorimetric changes quantified by measuring the absorbance in a spectrophotometer at 450 nm. And cell division times are calculated from eosin counting in parallel with viability assay
    (Only for Reference)
Animal Research:[4]
+ Expand
  • Animal Models: Brown Norway rat with myelocytic leukaemia
  • Formulation: Dissolved in phosphate-buffered saline (pH 7.0) just before use.
  • Dosages: 5 - 1000 mg/kg
  • Administration: Injection i.v.
    (Only for Reference)

Solubility (25°C)

In vitro Water 48 mg/mL (197.35 mM)
DMSO 1 mg/mL (4.11 mM)
Ethanol Insoluble
In vivo Add solvents to the product individually and in order:
Saline
For best results, use promptly after mixing.
30 mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 243.22
Formula

C9H13N3O5

CAS No. 147-94-4
Storage powder
Synonyms N/A

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT02756962 Recruiting Acute Myeloid Leukemia Washington University School of Medicine July 6, 2016 Phase 2
NCT01555268 Completed Adult Acute Megakaryoblastic Leukemia (M7)|Adult Acute Minimally Differentiated Myeloid Leukemia (M0)|Adult Acute Monoblastic Leukemia (M5a)|Adult Acute Monocytic Leukemia (M5b)|Adult Acute Myeloblastic Leukemia With Maturation (M2)|Adult Acute Myeloblastic Leukemia Without Maturation (M1)|Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities|Adult Acute Myeloid Leukemia With Del(5q)|Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)|Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)|Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)|Adult Acute Myelomonocytic Leukemia (M4)|Adult Erythroleukemia (M6a)|Adult Pure Erythroid Leukemia (M6b)|Recurrent Adult Acute Myeloid Leukemia|Untreated Adult Acute Myeloid Leukemia Roswell Park Cancer Institute|National Cancer Institute (NCI)|Amgen October 31, 2011 Phase 1
NCT02203526 Suspended Primary Central Nervious System Lymphoma National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) July 24, 2014 Phase 1
NCT03007147 Not yet recruiting B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1|BCR-ABL1 Fusion Protein Expression|Minimal Residual Disease|Philadelphia Chromosome Positive|T Acute Lymphoblastic Leukemia|Untreated Adult Acute Lymphoblastic Leukemia|Untreated Childhood Acute Lymphoblastic Leukemia Childrens Oncology Group|National Cancer Institute (NCI) July 2017 Phase 3
NCT02483000 Not yet recruiting Adult Burkitt Lymphoma|Adult Diffuse Large B-Cell Lymphoma|CD20-Positive Neoplastic Cells Present|Indolent Adult Non-Hodgkin Lymphoma|Mantle Cell Lymphoma|Recurrent B-Cell Non-Hodgkin Lymphoma|Refractory Mature B-Cell Non-Hodgkin Lymphoma Fred Hutchinson Cancer Research Center|National Cancer Institute (NCI) March 2017 Phase 1
NCT03019640 Not yet recruiting B-Cell Non-Hodgkin Lymphoma M.D. Anderson Cancer Center March 2017 Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

DNA/RNA Synthesis Signaling Pathway Map

Related DNA/RNA Synthesis Products

Tags: buy Cytarabine | Cytarabine supplier | purchase Cytarabine | Cytarabine cost | Cytarabine manufacturer | order Cytarabine | Cytarabine distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID